InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,815.03
(
0.61%
)
US TECH 100
19,700.00
(
-0.02%
)
Dow Jones
42,863.86
(
0.97%
)
Brent Oil
78.70
(
0.00%
)
Bitcoin
62,823.27
(
-0.58%
)
Post# of 253355
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 840
Posts 120561
Boards Moderated 14
Alias Born 09/05/2002

DewDiligence

Member Level

Re: EYEBUYSTOX post# 125024

Thursday, 08/11/2011 6:40:04 PM

Thursday, August 11, 2011 6:40:04 PM

Post# of 253355

FCSC—it's naive of you to think VRX would have no interest in a product that could be marketed to millions of acne scar sufferers with few other viable options.

VRX is looking for dermatology products it can sell. We can talk about acne scars when there are clinical data to show that laViv is safe and effective in that indication, which will be several years from now, if ever.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up